P-m6Ade-Ribf-P | 1359697-50-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: P-m6Ade-Ribf-P
• 英文别名: [(2R,3S,4R,5R)-4-hydroxy-5-[6-(methylamino)purin-9-yl]-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate
• CAS: 1359697-50-9
• 化学式: C₁₁H₁₇N₅O₁₀P₂
• 分子量: 441.231
• InChiKey: ZOVCQIPOEDRWLZ-IOSLPCCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  219
• 氢给体数：
  6
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  N⁶-methyladenosine 在 四氯三氧化二磷 作用下， 以4 %的产率得到P-m6Ade-Ribf-P
  参考文献：
  名称：

  通过化学酶促合成用修饰的和 19 F 标记的核苷酸对 RNA 进行位点特异性标记

  摘要：

  提出了一个转录后修饰和合成修饰核苷库，用于应用化学酶法对 RNA 进行位点特异性改变。这种方法克服了其他已建立和众所周知的 RNA 合成技术的局限性。通过使用氟化核苷对核糖开关进行位点特异性修饰以进行基于 NMR 的分析，证明了这种方法对生物系统的适用性。

  DOI：

  10.1002/chem.202203368

文献信息

• Aberrant Cyclization Affords a C-6 Modified Cyclic Adenosine 5′-Diphosphoribose Analogue with Biological Activity in Jurkat T Cells
  作者：Christelle Moreau、Tanja Kirchberger、Bo Zhang、Mark P. Thomas、Karin Weber、Andreas H. Guse、Barry V. L. Potter

  DOI：10.1021/jm201127y

  日期：2012.2.23

  Two nicotinamide adenine dinucleotide (NAD(+)) analogues modified at the 6 position of the purine ring were synthesized, and their substrate properties toward Aplysia californica ADP-ribosyl cyclase were investigated. 6-N-Methyl NAD(+) (6-N-methyl nicotinamide adenosine 5'-dinucleotide 10) hydrolyzes to give the linear 6-N-methyl ADPR (adenosine 5'-diphosphoribose, 11), whereas 6-thio NHD+ (nicotinamide 6-mercaptopurine 5'-dinucleotide, 17) generates a cyclic dinucleotide. Surprisingly, NMR correlation spectra confirm this compound to be the N1 cyclic product 6-thio N1-cIDPR (6-thio cyclic inosine 5'-diphosphoribose, 3), although the corresponding 6-oxo analogue is well-known to cyclize at N7. In Jurkat T cells, unlike the parent cyclic inosine 5'-diphosphoribose N1-cIDPR 2, 6-thio N1-cIDPR antagonizes both cADPR- and N1-cIDPR-induced Ca2+ release but possesses weak agonist activity at higher concentration. 3 is thus identified as the first C-6 modified cADPR (cyclic adenosine 5'-diphosphoribose) analogue antagonist; it represents the first example of a fluorescent N1-cyclized cADPR analogue and is a new pharmacological tool for intervention in the cADPR pathway of cellular signaling.
• Gpr17 modulators,method of screening and uses thereof
  申请人：Abbracchio Maria Pia

  公开号：US20090156521A1

  公开（公告）日：2009-06-18

  The invention provides GPR17 modulators, methods of screening and use thereof for diagnosis and therapy of diseases or dysfunctions involving GPR17 activation, particularly ischemic brain damage.
• US8158593B2
  申请人：——

  公开号：US8158593B2

  公开（公告）日：2012-04-17